新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » BIOON报道 » CytomX抗体药物有望成胰腺癌特效药

CytomX抗体药物有望成胰腺癌特效药

来源:生物谷 2013-10-29 20:12

2013年10月29日讯 /生物谷BIOON/ --位于旧金山的生物技术公司CytomX最近公布了其治疗胰腺癌的抗体药物CTX-033的具体研究数据,数据显示这种药物对胰腺癌肿瘤细胞具有很强靶向性,在单独治疗以及联合给药中都有显着疗效。CTX-033杀伤胰腺癌肿瘤细胞的原理在于阻断癌细胞Notch通路,这条通路与许多种癌症都有密切关系。胰腺癌被认为是最难以治疗的癌症种类之一,目前其五年存活率大约为6%。因此CytomX公司的抗体药物研究受到各方的关注。今年四月,辉瑞就和CytomX公司签订了合作研发协议。(生物谷Bioon.com)

详细英文报道:

Startup CytomX has unveiled new preclinical data showing that its fast-working antibody was effective in pancreatic cancer models as both a single agent and in combination with a currently approved cancer drug.

A highly effective target for pancreatic cancer has long eluded scientists. An extremely deadly form of cancer, it has an overall 5-year survival rate of about 6%. The San Francisco-based company announced the results this week at the International Conference on Molecular Targets and Cancer Therapeutics, hosted by the American Association for Cancer Research, the National Cancer Institute and the European Organisation for Research and Treatment of Cancer.

CTX-033, CytomX's anti-Jagged Probody is a masked antibody that leaves healthy tissue intact but is activated or "unmasked" once it finds cancer cells. CytomX's novel, first-in-class Probody program blocks Notch signaling by both the Jagged-1 and Jagged-2 ligands locally in the tumor microenvironment. The drug killed pancreatic cancer cells both on its own and alongside gemcitabine, a currently available anti-metabolite drug approved by the FDA to treat pancreatic and other cancers.

"The Notch pathway is centrally implicated in tumor biology and is involved in the progression of a number of cancers, including pancreatic cancer, triple negative breast cancer and multiple myeloma," Henry Lowman, chief scientific officer of CytomX, said in a statement. "Our anti-Jagged Probody represents a novel approach to targeting the Notch signaling pathway, and our data establish preclinical proof-of-concept that selective activation of CTX-033 in the tumor microenvironment results in robust efficacy with an acceptable therapeutic index."

The company's probody platform has attracted the attention of Big Pharma. In June, Pfizer ($PFE) sought out CytomX as a partner to find next-gen antibody-drug conjugates for cancer targets. Under the deal, CytomX will reap $25 million in near-term payments and research support with a promise of up to $610 million more in payments from back-ended sales and regulatory milestones plus a royalty stream on any approved therapies.

 

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库